Entod Pharmaceuticals, a Mumbai-based drug company, has made a groundbreaking advancement in eye care with the approval of PresVu, India’s first eye drops developed to reduce dependency on reading glasses for individuals with presbyopia. This innovative solution, targeting a common age-related vision condition, has received final approval from the Drug Controller General of India (DCGI) and will be launched in October.
What is Presbyopia? Presbyopia is a natural part of aging that affects the ability of the eye to focus on close objects. Typically beginning around the age of 40, it impacts over a billion people globally. People with presbyopia usually rely on reading glasses to see clearly at short distances. PresVu eye drops are positioned as a non-invasive, simple solution for this widespread issue.
PresVu: A Revolutionary Eye Drop PresVu eye drops were developed by Entod Pharmaceuticals and approved based on the recommendation of the Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO). These eye drops aim to give individuals suffering from presbyopia more independence by reducing their need for reading glasses.
According to Nikkhil K Masurkar, CEO of Entod Pharmaceuticals, “PresVu is more than just a product; it’s a solution that stands to improve the lives of millions by offering them greater visual independence.”
How Does PresVu Work? PresVu offers a non-invasive solution to enhance near vision without the need for corrective lenses. This unique formulation, leveraging advanced technology, also acts as a lubricant for the eyes, making it a dual-purpose product for treating presbyopia while ensuring long-term comfort.
Expanding Access to Eye Care While India remains the primary focus, Entod Pharmaceuticals is also exploring emerging markets such as Africa and Southeast Asia, where access to affordable healthcare solutions is a challenge. By catering to underserved regions, the company hopes to make PresVu available to those who need it the most. Beyond India, the company plans to innovate further and eventually enter the U.S. market, shifting its focus from low-cost generics to globally innovative products.
A Step Towards Innovation In addition to ophthalmology, Entod Pharmaceuticals is working in other therapeutic areas such as ENT and dermatology. Looking forward, the company has expressed interest in entering the mental health segment, citing it as an area of immense potential in India.
Conclusion The approval of PresVu is a significant step forward in addressing presbyopia, offering a simple yet effective alternative to reading glasses. With its innovative approach to eye care, Entod Pharmaceuticals is not only focusing on India’s vast market but also expanding its presence in emerging economies where access to advanced healthcare is limited.
As the company continues to grow and innovate, PresVu is expected to make a lasting impact on the lives of individuals worldwide, offering a brighter future for those with presbyopia.
To register for our next masterclass please click here https://linktr.ee/docpreneur
